Technical Analysis for SNDX - Syndax Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 5.11 -1.35% -0.07
SNDX closed down 1.35 percent on Tuesday, March 19, 2019, on 1.13 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical SNDX trend table...

Date Alert Name Type % Chg
Mar 19 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Mar 19 NR7 Range Contraction 0.00%
Mar 19 Wide Bands Range Expansion 0.00%
Mar 19 Oversold Stochastic Weakness 0.00%
Mar 18 Bullish Engulfing Bullish -1.35%
Mar 18 Wide Bands Range Expansion -1.35%
Mar 18 Oversold Stochastic Weakness -1.35%
Mar 15 Calm After Storm Range Contraction -0.20%
Mar 15 Lower Bollinger Band Walk Weakness -0.20%
Mar 15 Outside Day Range Expansion -0.20%

Older signals for SNDX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company's lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute; and Genentech. Syndax Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Waltham, Massachusetts.
Medicine Chemistry Cancer Clinical Medicine Solid Tumors Breast Cancer Antineoplastic Drugs Lung Cancer Pyridines Cancer Therapies Hematological Malignancies Late Stage Biopharmaceutical Benzamides Carbamates National Cancer Institute
Is SNDX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.2
52 Week Low 3.39
Average Volume 136,479
200-Day Moving Average 6.3438
50-Day Moving Average 5.8854
20-Day Moving Average 5.9025
10-Day Moving Average 5.447
Average True Range 0.3856
ADX 25.55
+DI 16.4965
-DI 25.1857
Chandelier Exit (Long, 3 ATRs ) 5.9532
Chandelier Exit (Short, 3 ATRs ) 6.1368
Upper Bollinger Band 7.0482
Lower Bollinger Band 4.7568
Percent B (%b) 0.15
BandWidth 38.820839
MACD Line -0.2183
MACD Signal Line -0.0769
MACD Histogram -0.1415
Fundamentals Value
Market Cap 113.54 Million
Num Shares 22.2 Million
EPS -2.84
Price-to-Earnings (P/E) Ratio -1.80
Price-to-Sales 191.23
Price-to-Book 2.13
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.46
Resistance 3 (R3) 5.47 5.38 5.40
Resistance 2 (R2) 5.38 5.29 5.37 5.38
Resistance 1 (R1) 5.24 5.23 5.20 5.23 5.36
Pivot Point 5.15 5.15 5.12 5.14 5.15
Support 1 (S1) 5.01 5.06 4.97 5.00 4.86
Support 2 (S2) 4.92 5.00 4.91 4.84
Support 3 (S3) 4.78 4.92 4.82
Support 4 (S4) 4.77